Ranolazine NDC 72578-065

NDC codes

FDA NDC Directory

Product NDC (as listed)72578-065Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72578-0065Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
72578-065-01	72578006501	100 TABLET, EXTENDED RELEASE in 1 BOTTLE (72578-065-01)Marketed from Sep 10, 2019
72578-065-05	72578006505	500 TABLET, EXTENDED RELEASE in 1 BOTTLE (72578-065-05)Marketed from Sep 10, 2019
72578-065-14	72578006514	60 TABLET, EXTENDED RELEASE in 1 BOTTLE (72578-065-14)Marketed from Sep 10, 2019
72578-065-77	72578006577	10 BLISTER PACK in 1 CARTON (72578-065-77) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (72578-065-30)Marketed from Sep 10, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ranolazine
Generic name (nonproprietary): ranolazine
Active ingredients: Ranolazine — 1000 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Viona Pharmaceuticals Inc
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210188
Marketing start: Sep 10, 2019
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2D6 Inhibitors (Mechanism)Cytochrome P450 3A Inhibitors (Mechanism)Organic Cation Transporter 2 Inhibitors (Mechanism)P-Glycoprotein Inhibitors (Mechanism)
Identifiers: Product ID 72578-065_ca6a476b-e330-4618-8661-08ac1125fc3eSPL ID ca6a476b-e330-4618-8661-08ac1125fc3eSPL set ID 00979fb3-d70f-493d-94ca-2914cbadaa9dRxCUI 616749, 728231UNII A6IEZ5M406
Pharmacologic class: Anti-anginal

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472578006501 followed by a unit qualifier and the quantity

Package 72578-0065-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 29, 2026.

Indications (excerpt from the label)

Ranolazine extended-release tablet is indicated for the treatment of chronic angina. Ranolazine extended-release tablet may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. Ranolazine extended-release tablet is an antianginal indicated for the treatment of chronic angina. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)